ABSTRACT
Background: Echocardiographic markers associated with asymptomatic acute cellular rejection (ACR) in patients with orthotopic heart transplant (HT) are still under investigation. The aim of our study was to determine clinical and myocardial strain imaging (MSI) variables evaluated by echocardiography associated with ACR in the first year of HT. A separate analysis was performed to compare variables during the first 6 months of HT, when ACR has a prevalence in 60% of patients. Another analysis evaluated an exclusive population with Chagas disease as the cause of HT. Methods: We prospectively studied 67 patients with less than 1 year of HT, 36 patients without ACR (41% men, age 49 ± 12 years, 52% Chagas disease as the cause of heart failure), and 31 patients with ACR (59% men, age 55 ± 8 years, 74% Chagas disease as the cause of heart failure). Conventional echocardiographic measurements and MSI by global longitudinal strain (GLS) from the left ventricle (LV) and right ventricle free wall (RV-FWLS) and myocardial work (MW) from the left ventricle were obtained by experienced echocardiologists. Clinical variables, such as the presence of diabetes, hypertension, and immunosuppressant drugs, were compared between groups. Results: HT patients with ACR were older and used more cyclosporine for immunosuppression. The positive ACR group had an increased relative wall thickness and LV mass index and similar LVGLS and RV-FWLS compared to the negative ACR group. Nevertheless, MW analysis observed increased global work efficiency (GWE) in positive ACR. Multivariate analysis identified older age, cyclosporine use, LV mass index, and GWE as independent predictors for detecting rejection. A separate analysis was performed for patients with less than 6 months of HT. Similar MSI was observed in both groups, with a trend for increased GWE in patients with ACR and significantly increased LV mass index in the ACR group. An exclusive group of Chagas patients as the primary cause of HT was analyzed, and similar MSI results for LVGLS, RV-FWLS, and MW were observed for both ACR and the no rejection groups. Additionally, the survival rates at 2 years were similar between the Chagas disease groups. Conclusion: LVGLS and RV-FWLS were similar between patients with or without ACR in the first year after HT. Conversely, GWE, a derivative of LVGLS, and LV mass index were increased in positive ACR and could be markers for rejection. Increased LV mass index was also found in a subgroup analysis of patients less than 6 months after HT; however, MSI was similar regardless of ACR. For chagasic patients, rejection in the first year did not increase mortality at the 2-year follow-up, and MSI parameters were similar between patients with or without ACR. In a multivariate analysis to predict ACR, the independent parameters in this study were older age, cyclosporine use, LV mass index, and GWE.
ABSTRACT
Introdução: O ecocardiograma transesofágico é atualmente uma das principais ferramentas no diagnóstico de diversas alterações cardíacas. Para uma maior segurança e conforto na sua realização, o exame tem sido realizado sob sedação consciente moderada, sendo os benzodiazepínicos os agentes de escolha. Nessa classe de medicamentos, o midazolam é o mais utilizado, todavia não está isento de possíveis complicações relacionadas ao seu uso, como hipóxia, hipotensão, entre outras. Sabemos que grau de sedação é dose-dependente, portanto, quanto menor a dose utilizada, será menor o risco de complicações do procedimento.Objetivo: Verificar o impacto do uso do fentanil na administração endovenosa de midazolam, no intuito de avaliar eficiência de protocolo de sedação de pacientes submetidos a ecocardiograma transesofágico, utilizando ambos os medicamentos. Metodologia: : Estudamos 201 pacientes (idade média de 51,5 anos, 115 homens) submetidos a ecocardiograma transesofágico, com sedação por via endovenosa divididos em dois grupos: Grupo A (n = 89), seguindo protocolo definido com uso de fentanil associado ao midazolam; e Grupo B (n = 112), sem o emprego de fentanil. Comparou-se então a dosagem de midazolam administrada em ambos os grupos. Monitorização adequada dos sinais vitais foi realizada durante todo o procedimento. Resultados: A dose média de midazolam utilizada foide 2,6 ± 1,4 mg no Grupo A e de 4,0 ± 2,7 mg no Grupo B (p < 0,01). A dose de fentanil empregada foi de 66,2 ± 24,8 mcg. Não houve diferença significativa entre idade (p = 0,08) e gênero (p > 0,1) nos grupos estudados. Conclusão: O uso de fentanil na sedação para realização de ecocardiograma transesofágico associado à administração de midazolam permite a administração de uma dose menor desse benzodiazepínico.
Introduction: Transesophageal echocardiography is currently one of the main tools in the diagnosis of various cardiac abnormalities. For greater safety and comfort, the test has been performed under moderate conscious sedation and benzodiazepines were the agents of choice. In this class of drugs, midazolam is the most commonly used, however it is not free of potential complications related to its use, such as hypoxia, hypotension, among others. We know that sedation level is dose-dependent. Therefore, the lower the dose, the lower the risk of complications from the procedure.Objective: To check the impact of fentanyl in the intravenous administration of midazolam in order to assess the sedation protocol efficiency on patients undergoing transesophageal echocardiography using both drugs.Methodology: We have studied 201 patients (mean age 51.5 years, 115 men) who underwent transesophageal echocardiography with intravenous sedation divided into two groups: Group A (n = 89), following the protocol with fentanyl associated with midazolam; and Group B (n = 112) without the use of fentanyl. The dose of midazolam administered in both groups was then compared. Proper monitoring of vital signs was performed throughout the procedure.Results: The mean dose of midazolam used was 2.6 ± 1.4 mg in Group A and 4.0 ± 2.7 mg in Group B (p < 0.01). The dose of fentanyl used was 66.2 ± 24.8 mcg. There was no significant difference between age (p = 0.08) and gender (p > 0.1) in the groups studied. Conclusion: The use of fentanyl in sedation for transesophageal echocardiography associated with administration of midazolam allows the administration of a lower dose of this benzodiazepine.
Introducción: El ecocardiograma transesofágico es actualmente una de las principales herramientas en el diagnóstico de diversas alteraciones cardíacas. Para una mayor seguridad y confort en su realización, el examen ha sido realizado bajo sedación conciente moderada, siendo los benzodiazepínicos los agentes de elección. En esa clase de medicamentos, el midazolam es el más utilizado, sin embargo no está exento de posibles complicaciones relacionadas a su uso, como hipoxia, hipotensión, entre otras. Sabemos que grado de sedación es dosis-dependiente, por lo tanto, cuanto menor es la dosis utilizada, será menor el riesgo de complicaciones del procedimiento.Objetivo: Verificar el impacto del uso del fentanil en la administración endovenosa de midazolam, con el propósito de evaluar eficiencia de protocolo de sedación de pacientes sometidos a ecocardiograma transesofágico, utilizando ambos medicamentos.Metodología: Estudiamos 201 pacientes (edad media de 51,5 anos, 115 hombres) sometidos a ecocardiograma transesofágico, con sedación por vía endovenosa divididos en dos grupos: Grupo A (n = 89), siguiendo protocolo definido con uso de fentanil asociado al midazolam; y Grupo B (n = 112), sin el empleo de fentanil. Se comparó entonces el dosaje de midazolam administrada en ambos grupos. Monitoreo adecuado de los signos vitales fue realizada durante todo el procedimiento. Resultados: La dosis media de midazolam utilizada fue de 2,6 ± 1,4 mg en el Grupo A y de 4,0 ± 2,7 mg en el Grupo B (p < 0,01). La dosis de fentanil empleada fue de 66,2 ± 24,8 mcg. No hubo diferencia significativa entre edad (p = 0,08) y género (p > 0,1) en los grupos estudiados. Conclusión: El uso de fentanil en la sedación para realización de ecocardiograma transesofágico asociado a la administración de midazolam permite la administración de una dosis menor de ese benzodiazepínico
